Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | FURIN | P09958 | 1/20 | 0.39 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.39 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4624320 | 1.00 | CA12 (0.44) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL12848022 | 1.00 | CA12 (0.44) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL26049411 | 0.94 | CA12 (0.40) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL6756919 | 0.92 | GAA (0.40) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL6756922 | 0.92 | GAA (0.40) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL14454603 | 0.92 | CA12 (0.39) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL965125 | 0.92 | PKM (0.47) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL19880237 | 0.91 | CA12 (0.39) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL14454598 | 0.91 | RAB9A (0.41) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL14454596 | 0.91 | CA12 (0.43) | CA12CA1CA2CA9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1344109-B1 | ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS | CIBA HOLDING INC (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-6929896-B2 | Onium salts and the use therof as latent acids | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2005-08-16 | — | — | US | disclosed |
| US-6713612-B2 | Sulfonyldiazomethanes, photoacid generators, resist compositions, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| US-20040053158-A1 | Onium salts and the use therof as latent acids | CIBA SPECIALTY CHEMICALS CORP. | 2004-03-18 | — | — | US | disclosed |
| US-20030224298-A1 | Novel sulfonyldiazomethanes, photoacid generators, resist compositions, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030224298-A1 | Novel sulfonyldiazomethanes, photoacid generators, resist compositions, and patterning process | VEGFA, DNMT3A, PIM3 | CA12 3341/4885CA1 3621/4885CA2 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.